GSK is a fully focused biopharma company. We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics, genomics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We focus on four therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology,
New global analysis across five cities shows inequities in adult immunisation uptake, signalling need to redesign local and national policy interventions December 6, 2023 11:38am
Findings to be presented at the Global Coalition on Aging’s Silver Economy Forum 2023.
View this post
New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence November 30, 2023 3:31am
A new GSK survey shows a large number of adults do not understand how shingles may be triggered.
View this post
GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple myeloma November 27, 2023 1:36am
Blenrep plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex.
View this post
GSK announces major step towards sustainability ambitions with advancement of low carbon Ventolin programme to Phase III trials November 21, 2023 3:00am
Next-generation propellant technology has the potential to reduce greenhouse gas emissions from Ventolin (salbutamol) inhaler.
View this post
GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia November 13, 2023 12:23pm
Decision on EU marketing authorisation expected for momelotinib by early 2024.
View this post
Strong year-to-date and Q3 performance drives upgrade to full-year guidance November 1, 2023 3:00am
Q3 2023 performance highlights
View this post
